Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Sagimet Biosciences is a biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors to treat metabolic liver diseases like MASH, acne, and certain cancers. Its lead candidate, denifanstat, is an oral pill targeting liver fat, inflammation, and fibrosis. The company focuses on precision medicine, biomarker-driven development, and strategic collaborations to address unmet medical needs in hepatology and oncology.
This description was generated via AI from an annual report. Updated about 1 year ago.